| Literature DB >> 27776123 |
Sushmita Das1, Rakesh Mandal2, Vidya Nand Rabidas3, Neena Verma4, Krishna Pandey3, Ashok Kumar Ghosh5, Sreekant Kesari2, Ashish Kumar4, Bidyut Purkait4, Chandra Sekhar Lal3, Pradeep Das4.
Abstract
BACKGROUND: Visceral leishmaniasis (VL), with the squeal of Post-kala-azar dermal leishmaniasis (PKDL), is a global threat for health. Studies have shown sodium stibogluconate (SSG) resistance in VL patients with chronic arsenic exposure. Here, we assessed the association between arsenic exposure and risk of developing PKDL in treated VL patients.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27776123 PMCID: PMC5077161 DOI: 10.1371/journal.pntd.0005060
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Map of the study cohort.
A. Map of Bihar state, India with the boxed study cohort. B. Detailed map of Raghopur block showing the study cohort with seven villages of interest; details of water bodies, land and inhabitant distribution.
Fig 2Flow chart of the study population.
Flow chart of the study population from PKDL patients who were treated at Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, Bihar between 2009 and 2014.
Comparative status for history of VL episode of the PKDL cases in the study cohort.
| Study groups in the cohort | Group A: PKDL patients treated with SSG during VL episode (n = 108) | Group B: PKDL patients treated with other drugs during VL episode (n = 31) |
|---|---|---|
| No | 97 (89.8%) | 26 (83.8%) |
| Yes | 10 (9.2%) | 4 (12.9%) |
| 0–5 | 95 (87.9%) | 25 (80.6%) |
| >5 | 13 (12.03%) | 6 (19.3%) |
| No | 37 (34.2%) | 9 (29.03%) |
| Yes | 71 (65.7%) | 22 (70.9%) |
| Failure | 28 (25.9%) | 5 (16.1%) |
| Success | 80 (74.07%) | 26 (83.8%) |
| Private clinic | 11 (10.1%) | 3 (9.6%) |
| Government center | 97 (89.8%) | 28 (90.3%) |
Selected confounders in the cohort.
| Arsenic concentration (μg/mL) in water sources | Baseline cohort (n = 139) | |
|---|---|---|
| Male | 117.2 (45.1) | 108 (77.6%) |
| Female | 109.4 (39.6) | 31 (22.3%) |
| 5–15 | 104.2 (22.3) | 27 (19.4%) |
| 16–30 | 121.4 (36.3) | 59 (42.4%) |
| 31–50 | 110.6 (39.4) | 39 (28.05%) |
| 51–70 | 107.1 (34.6) | 14 (10.07%) |
| <18.5 | 120.7 (31.6) | 73 (52.5%) |
| 18.5–24.9 | 102.6 (28.9) | 44 (31.6%) |
| ≥25 | 99.4 (22.8) | 22 (15.8%) |
| <140 | 109.3 (14.2) | 112 (80.5%) |
| ≥140 | 98.7 (22.5) | 27 (19.4%) |
| 0 | 112.4 (24.7) | 45 (32.3%) |
| 1–10 | 101.7 (18.6) | 84 (60.4%) |
| 11–15 | 91.6 (24.4) | 10 (7.1%) |
| Higher | 84.6 (32.5) | 31 (22.3%) |
| Backward | 110.1 (24.6) | 108 (77.6%) |
Fig 3Village-wise PKDL case distribution.
Village-wise PKDL case distribution in the study cohort of Raghopur block, Vaishali district, Bihar, India.
Fig 4Distribution of arsenic contamination in groundwater and PKDL cases in the study cohort.
A: Map of Raghopur block showing spatial distribution of inhabitants, B. Distribution of arsenic in groundwater in seven villages of the study cohort, C. Overlap of location of PKDL cases with distribution of arsenic in groundwater in seven villages of the study cohort.
Fig 5Distribution of PKDL cases in respect to variable arsenic concentrations in the study cohort.
Odds ratios (ORs) for risk of PKDL development in the study participants in association to arsenic exposure.
| PKDL development (n = 139) | |||
|---|---|---|---|
| OR (95% CI) | Z statistics | P value | |
| 0.1–10.0 | 1.0 | ||
| 10.1–200.0 | 1.85 (1.13–3.03) | 2.46 | 0.01 |
| 200.1–432.0 | 2.31 (1.39–3.8) | 3.2 | 0.001 |
| 0.05–50.0 | 1.0 | ||
| 50.1–247.0 | 1.32 (0.77–2.25) | 1.03 | 0.2 |
| 247.1–1076.0 | 1.21 (0.71–2.03) | 0.72 | 0.4 |
| 5.0–123.0 | 1.0 | ||
| 123.1–436.0 | 1.35 (0.80–2.28) | 1.13 | 0.25 |
| 436.1–1278.0 | 1.40 (0.87–2.25) | 1.4 | 0.16 |
| 1278.1–4000.0 | 1.61 (0.99–2.6) | 1.9 | 0.05 |
*Multivariate analysis were adjusted for confounders body-mass index (BMI in kg/m2), systolic blood pressure (mm Hg), caste status, fundamental education (in years), previous VL treatment with SSG or any other drug in the family etc.